Assessing ethnic sensitivity by simulating pharmacokinetics in virtual Caucasian and Chinese populat

来源 :第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu | 被引量 : 0次 | 上传用户:sophia_je
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Background and Rationale: Physiologically-based pharmacokinetics (PBPK) modelling is a key component of model-based drug development and is increasingly embraced within the industry and regulatory authorities.PBPK is a useful tool to simulate PK profiles in various ethnic groups and can be used as the first step to assess ethnic sensitivity.Currently, commercially available PBPK models use parameters gathered mainly in Caucasians while the population data in Chinese is yet to be collected.In addition, the data and model of Chinese population are new and need more evaluation for prospective application.Objective:Firstly, to.evaluate the omeprazole PBPK model in Chinese, assess the likely ethnical differences between Chinese and Caucasian populations in the kinetics of CYP2C19 substrates arising from demographic, physiological and genetic differences and design better bridge clinical studies.Secondly, to predict the difference in pharmacokinetics of Omeprazole in Caucasian and Chinese using the qualified model.Method:Omeprazole PBPK model built by SimCYP (Version 12) was applied through incorporating Chinese population specific data (demographic, physiological and enzyme information) collated from literature sources [1].The omeprazole model consists of Advanced Dissolution, Absorption and Metabolism (ADAM) Model and minimal PBPK model for absorption and volume of distribution, respectively.The clearance is scaled using the following equation for both CYP3A4 and CYP2C19 pathways: CLuH,int=CLu,int×abundance×MPPGL×Liver weight[2].MPPGL is microsomal protein per gram of liver.The published in vivo PK data in Chinese were used as the observed values.Omeprazole was administrated orally in two papers and intravenously in one paper [3-5].Virtual subjects (n=100) generated within SimCYP are matched to the subjects used in the published papers with respect to age, body weight, height, sex, dosage and phenotype.CYP2C19 is known as the major metabolic pathway of Omeprazole for the extensive metabolizers (EM), and the genotypes of*1/*1, *1/*2, *1/*3 are known as the EMs.The PK data of the EM subjects are used to evaluate the model in Chinese for the CYP2C19 substrate Omeprazole.Similarly, the PK data of the PM subjects are used for the PM model evaluation (i.e., CYP3A4 metabolism of Omeprazole).This is accomplished by plotting the observed data of individual subjects overlaying with the model based 90% prediction interval (shaded area).In addition, the PK parameters (AUC and Cmax) are compared.Once the model is confirmed with acceptable errors, simulations of the population PKs of Omeprazole in both Chinese and Caucasians can be produced based on the frequencies of EM and PM for 2C19 in the two populations and their differences can be calculated.Result:Discussion and conclusion:The discrepancy between simulation and observation is within 2-fold.The existing CYP2C19 data in the Simcyp can be used to simulate PK of CYP2C 19 substrates in Chinese.The difference in PK of omeprazole in Caucasian and Chinese may be mainly caused by the difference of abundance of CYP2C 19 followed by body weight.Extension of this work to predict PK of other CYP substrates in Chinese is indicated.
其他文献
Esomeprazole has proved to be effective for the treatment of gastroesophogeal reflux disease (GERD) and ulcers, where intra-gastric pH value is a biomarker to indicate esomeprazole effects on these di
会议
Background: The distribution of renal function and its effect on drug elimination was not well understood in Chinese population, which impeded the clinical therapeutics for Chinese patients as well as
会议
Aim:Rivaroxaban (Bayer Healthcare AG, Wuppertal, Germany), an oral, direct factor Xa (FXa) inhibitor for the prevention and treatment of thromboembolic disorders has been approved for nonvalvular atri
会议
Aim:Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal growth factor receptor (EGFR) tyrosine kinase.The aim of this study was to investigate the relationship betwe
Purpose:To investigate the pharmacological effects of differenterlotinib (ER) and gemcitabine (GM) combination schedules byin vitro and in vivo experiments and PK/PD models in non-smallcell lung cance
会议
Pediatric drug research is currently one of the new frontiers for clinical pharmacology.With the necessity of pediatric drug research and the special ethical considerations in pediatric clinical trial
会议
INTRODUCTION Drug discovery for central nervous system (CNS) disorders has been challenged with markedly high attrition rate.This has driven extensive preclinical and clinical CNS pharmacokinetic (PK)
会议
Background: Exposure-response model has been established in patients with psoriasis for Ustekinumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that binds with high affinity to human
会议
AIM: To develop a population pharmacokinetic model of adefovir dipivoxil in healthy volunteers and evaluate the effect of individual factors on the pharmacokinetics of adefovir dipivoxil.METHODS: Plas
会议
The objective of this study was to assess ethnic difference of mycophenolic acid (MPA) and 7-Omycophenolic acid glucuronide (MPAG) pharmacokinetics (PK) among Chinese and Caucasian healthy subjects by
会议